Onco Actu du 16 novembre 2017

	3.1.1 Prévention - Tabac - e-cigs
'Vaping should be part of support' to help smokers with mental health conditions quit [Cancer Research UK] McNeill said the statement aimed to address some of the widespread misunderstandings about e-cigarettes, and hoped it will support mental health staff and organisations in thinking about how they can encourage more of their service users to quit smoking.
	3.7 Prévention - Alcool
Minimum alcohol pricing in Scotland gets go ahead [Cancer Research UK] The UK Supreme Court has dismissed a challenge against new legislation that allows Scotland to enforce minimum pricing on alcohol. The judges rejected an appeal from the Scotch Whisky Association (SWA), standing by the plan which aims to improve public health.
	4.10 Dép., diag. & prono. - FDA, EMA, NICE,...
FDA Announces Third-Party Review Pathway for Tumor Profiling Tests [RAPS] FDA says the IMPACT test is "highly accurate" and can identify mutations in more genes than any other test it has reviewed in the past. However, FDA says that while the results of the test can provide valuable insights to patients and physicians, its results alone "are not conclusive for choosing a corresponding treatment."
FDA unveils a streamlined path for the authorization of tumor profiling tests alongside its latest product action [FDA] Newly authorized test detects genetic cancer mutations in 468 unique genes.
FDA Authorizes MSK-IMPACT Test for Analyzing Patient Tumors [Memorial Sloan Kettering Cancer Center] MSK-IMPACT, which stands for integrated mutation profiling of actionable cancer targets, has been used to analyze the tumors of people with advanced cancer being treated at MSK since January 2014. It is based on a technology called high-throughput next-generation sequencing.
	5. Traitements
Pancreatic cancer is often deadly. But recent discoveries are starting to unravel its mysteries — and raise hope [STAT] Pancreatic cancer is the third-leading cause of cancer-related death in the U.S., recently surpassing breast cancer. Only lung and colon cancers have higher mortality rates. The new findings will take years to reach the clinic, but researchers say they could, perhaps, finally start to improve patients’ odds.
	5.12 Immunothérapies
Powerful new cancer drugs are saving lives, but can also ignite diabetes or other autoimmune conditions [Science] For oncologists thrilled with the spectacular results that checkpoint inhibitors can deliver, the key is to walk “a very fine line” between treating cancer and causing autoimmunity, says immunologist Brian Fife of the University of Minnesota in Minneapolis.
	5.12.2 Immunothérapies - CAR-T
Promising new CAR-T therapy able to target T-cell lymphoma [Pharmafile] Autolus has managed to find a potential workaround to be able to treat individuals with T-cell lymphoma by being discovering how to specifically target the cancerous T cells whilst leaving the healthy T cells to maintain the body’s protection against illness.
	5.12.7 Immunothérapies - vaccins
This $5 Billion Startup Made Its First Cancer Vaccine—For Just One Person [Bloomberg] Six weeks ago, a 1-millimeter cube of cancer tissue collected by doctors from the right lung of 67-year-old retiree Glenda Cleaver was packed in a box at the Sarah Cannon Research Institute in Nashville, Tennessee. It was the beginning of a journey Moderna hopes will lead to a long-sought goal: a vaccine that trains the body to attack tumors.
	5.2 Pharma
Takeda leverages lung cancer awareness month to highlight ALK variant [FiercePharma] Launched for lung cancer awareness month in November, the “tALK+” (Talk Positive) campaign focuses on the ALK-positive form of lung cancer, which affects between 2% and 8% of all non-small cell lung cancer patients.
	5.2.3 Pharma - économie
AstraZeneca, Merck, Clovis and Tesaro, all vying for share, may all win on faster PARP growth [FiercePharma] And for use earlier in the treatment line? The doctors showed "a high degree of enthusiasm regarding the potential use of PARP inhibitors in front-line maintenance ... particularly in BRCA+ patients.
	5.4 Traitements - Economie
Breast cancer patients to have routine access to two life extending drugs after new deal, say NICE in draft guidance [NICE] NICE has recommended palbociclib and ribociclib for routine funding after the companies lowered the prices and gave more evidence for their effectiveness.
Thousands to benefit as 'breakthrough' breast cancer drugs approved for NHS use [The Guardian] The drugs, called palbociclib and ribociclib, have been shown to slow the progression of advanced cancer by at least 10 months and can delay the need for chemotherapy, giving women the chance to live a normal life for longer.
Pfizer, Novartis agree UK price cuts for new breast cancer drugs [Reuters] Both are oral drugs, given in concert with hormonal therapies, that inhibit two proteins called CDK 4 and 6. They have the same official list price of 2,950 pounds ($3,882) for one cycle of treatment. The size of the discounts being offered by the manufacturers are commercially confidential.
	6. Lutte contre les cancers
Cancer Care in Low-Resource Areas: Cancer Treatment, Palliative Care, and Survivorship Care: Proceedings of a Workshop (2017) [NAP] The first workshop, held in October 2015, focused on cancer prevention and early detection. The second workshop was held in November 2016, and focused on cancer treatment, palliative care, and survivorship care in low-resource areas.
Novartis, ASCP and ACS join forces to fight cancer in Ethiopia, Uganda and Tanzania [ACS] Objective is to provide patients with rapid cancer diagnostics and appropriate care.
	6.1 Observation
African-American Women With Type 2 Diabetes May Have Higher Risk for ER-negative Breast Cancer [AACR] “Our findings may account for some of the racial disparity in breast cancer, and could partly explain why mortality from breast cancer is so much higher in black women than white women.”
	6.11 Patients
Tom Marsilje, a relentless advocate for cancer patients, dies at 45 [STAT] Marsilje, a Novartis scientist who helped develop a cutting-edge lung cancer treatment — and who, after his own colon cancer diagnosis, became a fierce advocate for his fellow patients — died Tuesday afternoon at a hospital in San Diego.
	6.12 Ethique
Bioethics: Justice in genomics [Nature] Reardon's underlying message is one of disappointment. She believes that genomics has enormous beneficial potential, but sees the human genome as a currency that so far has been deprived of value because, she alleges, of a lack of medical breakthroughs resulting from it. This is the major shortcoming of the book.
	6.6 Publications
Is There a Business Case for Open Data? [The Scholarly Kitchen] The document contains a number of thoughtful pieces from the European Commission, the Wellcome Trust, and Springer Nature (among others), as well as the results of Figshare’s second annual survey of researchers about their experiences with data sharing.
	6.9 Controverses
Placebo Myths Debunked [Science-Based Medicine] Desperate to salvage a role for their preferred but ineffective treatments, many alternative practitioners will argue that their real expertise is in maximizing placebo effects. OK, sure, the scientific evidence shows that my treatment is no better than placebo, but placebo effects are real, and I am very good at eliciting them. This is the “placebo medicine” gambit.
Economics: How science got a golden ticket [Nature] The era of scientists being left to run their own show may be drawing to a close if science is expected to make economic returns. You have been warned.